Share this article
Share this article
LA JOLLA, Calif., March 15, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress. In 2020, we made significant advances across our AOC pipeline and platform. Our work supports Avidity s evolution to a clinical-stage company as we plan to advance AOC 1001 into the clinic in the second half of this year and progress our FSHD and DMD programs, said Sarah Boyce, President and Chief Executive Officer. Our discovery efforts continue to focus on expanding our AOC platform into additional muscle diseases and other tissues as we begin to realize our vision of profoundly improving people s lives by revolutionizing the delivery of RNA treatments.
Canarias24Horas com - El Hospital Dr Negrín, galardonado en los premios nacionales TOP 20 en el área Músculo Esquelético
canarias24horas.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canarias24horas.com Daily Mail and Mail on Sunday newspapers.
Dos áreas del Negrín y Materno, galardonados como los mejores de España
canarias7.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canarias7.es Daily Mail and Mail on Sunday newspapers.